Does MMR status in endometrial cancer influence response to adjuvant therapy?
- 29 August 2018
- journal article
- research article
- Published by Elsevier BV in Gynecologic Oncology
- Vol. 151 (1), 76-81
- https://doi.org/10.1016/j.ygyno.2018.08.020
Abstract
No abstract availableKeywords
Funding Information
- University of British Columbia
This publication has 14 references indexed in Scilit:
- Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2016
- Clinicopathologic implications of DNA mismatch repair status in endometrial carcinomasGynecologic Oncology, 2015
- Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomasGynecologic Oncology, 2015
- Mismatch repair status and clinical outcome in endometrial cancer: A systematic review and meta-analysisCritical Reviews in Oncology/Hematology, 2013
- Molecular Pathways: Microsatellite Instability in Colorectal Cancer: Prognostic, Predictive, and Therapeutic ImplicationsClinical Cancer Research, 2012
- Clinicopathologic significance of DNA mismatch repair protein defects and endometrial cancer in women 40years of age and youngerGynecologic Oncology, 2011
- Testing Women With Endometrial Cancer to Detect Lynch SyndromeJournal of Clinical Oncology, 2011
- Current Hypotheses on How Microsatellite Instability Leads to Enhanced Survival of Lynch Syndrome PatientsClinical and Developmental Immunology, 2010
- Survival of hereditary non-polyposis colorectal cancer patients compared with sporadic colorectal cancer patientsJournal of Experimental & Clinical Cancer Research, 2008
- Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancerGut, 2006